Cache Advisors LLC Acquires Shares of 10,909 Gilead Sciences, Inc. (NASDAQ:GILD)

Cache Advisors LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,909 shares of the biopharmaceutical company’s stock, valued at approximately $1,008,000.

A number of other large investors also recently modified their holdings of GILD. HHM Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the 4th quarter worth $28,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences in the 4th quarter worth $31,000. Stephens Consulting LLC raised its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $33,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Up 0.6%

GILD stock opened at $107.37 on Friday. The stock has a 50-day simple moving average of $105.27 and a two-hundred day simple moving average of $100.30. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The firm has a market capitalization of $133.56 billion, a PE ratio of 290.19, a PEG ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences’s revenue was down .3% compared to the same quarter last year. During the same period last year, the business earned ($1.32) earnings per share. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.94%. Gilead Sciences’s payout ratio is currently 66.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Bank of America upped their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research report on Thursday, February 13th. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, April 25th. Finally, Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider now owns 121,152 shares of the company’s stock, valued at $13,026,263.04. This represents a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total value of $266,000.00. Following the sale, the chief financial officer now owns 168,174 shares in the company, valued at $17,893,713.60. The trade was a 1.46% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,929 shares of company stock worth $5,644,780. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.